Understanding Peripartum Cardiomyopathy

Literature Cited

1. Porak C. 1.  1880. De l'influence réciproque de la grossesse et des maladies du coeur Paris: Faculté de Médecine de Paris
2. Ritchie C. 2.  1849. Clinical contribution to the pathology, diagnosis, and treatment of certain chronic diseases of the heart. Edinburgh Med. Surg. J 185333–42 [Google Scholar]
3. Hull E, Hafkesbring E. 3.  1937. Toxic postpartal heart disease. New Orleans Med. Surg. J 89550 [Google Scholar]
4. Hull E, Hidden E. 4.  1938. Postpartal heart failure. South. Med. J 31265 [Google Scholar]
5. Demakis JG, Rahimtoola SH, Sutton GC. 5.  et al. 1971. Natural course of peripartum cardiomyopathy. Circulation 44:1053–61 [Google Scholar]
6. Demakis JG, Rahimtoola SH. 6.  1971. Peripartum cardiomyopathy. Circulation 44:964–83 [Google Scholar]
7. Sliwa K, Hilfiker-Kleiner D, Petrie MC. 7.  et al. 2011. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur. J. Heart Fail. 12:767–78 [Google Scholar]
8. Elkayam U. 8.  2014. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J. Am. Coll. Cardiol. 64:1629–36 [Google Scholar]
9. Mielniczuk LM, Williams K, Davis DR. 9.  et al. 2006. Frequency of peripartum cardiomyopathy. Am. J. Cardiol. 97:1765–68 [Google Scholar]
10. Brar SS, Khan SS, Sandhu GK. 10.  et al. 2007. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am. J. Cardiol. 100:302–4 [Google Scholar]
11. Gunderson EP, Croen LA, Chiang V. 11.  et al. 2011. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet. Gynecol. 118:583–91 [Google Scholar]
12. Kolte D, Khera S, Aronow WS. 12.  et al. 2014. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J. Am. Heart Assoc. 3:e001056 [Google Scholar]
13. Desai D, Moodley J, Naidoo D. 13.  1995. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop. Doctor 25:118–23 [Google Scholar]
14. Sliwa K, Damasceno A, Mayosi BM. 14.  2005. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 112:3577–83 [Google Scholar]
15. Hasan JA, Qureshi A, Ramejo BB, Kamran A. 15.  2010. Peripartum cardiomyopathy characteristics and outcome in a tertiary care hospital. J. Pakistan Med. Assoc 60377–80 [Google Scholar]
16. Pandit V, Shetty S, Kumar A, Sagir A. 16.  2009. Incidence and outcome of peripartum cardiomyopathy from a tertiary hospital in South India. Trop. Doctor 39:168–69 [Google Scholar]
17. Barasa A, Rosengren A, Sandstrom TZ. 17.  et al. 2017. Heart failure in late pregnancy and postpartum: incidence and long-term mortality in Sweden from 1997 to 2010. J. Cardiac Fail. 23:5370–78 [Google Scholar]
18. Fett JD, Christie LG, Carraway RD, Murphy JG. 18.  2005. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin. Proc. 80:1602–6 [Google Scholar]
19. Isezuo SA, Abubakar SA. 19.  2007. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. Ethn. Dis. 17:228–33 [Google Scholar]
20. Arany Z, Elkayam U. 20.  2016. Peripartum cardiomyopathy. Circulation 133:1397–409 [Google Scholar]
21. Bello N, Hurtado Rendon IS, Arany Z. 21.  2013. The relationship between preeclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 62:1715–23 [Google Scholar]
22. Irizarry O, Levine L, Lewey J. 22.  et al. 2017. Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and non-African American women. JAMA Cardiol 2:111256–60 [Google Scholar]
23. Banayan J, Rana S, Mueller A. 23.  et al. 2016. Cardiogenic shock in pregnancy: analysis from the National Inpatient Sample. Hypertens. Pregnancy 36:2117–23 [Google Scholar]
24. Cenac A, Gaultier Y, Devillechabrolle A, Moulias R. 24.  1988. Enterovirus infection in peripartum cardiomyopathy. Lancet 2:968–69 [Google Scholar]
25. Bultmann BD, Klingel K, Nabauer M. 25.  et al. 2005. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am. J. Obstet. Gynecol. 193:363–65 [Google Scholar]
26. Fett JD. 26.  2006. Viral particles in endomyocardial biopsy tissue from peripartum cardiomyopathy patients. Am. J. Obstet. Gynecol. 195:330–31 [Google Scholar]
27. Liu LX, Arany Z. 27.  2014. Maternal cardiac metabolism in pregnancy. Cardiovasc. Res. 101:545 [Google Scholar]
28. Pearson GD, Veille JC, Rahimtoola S. 28.  et al. 2000. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 283:1183–88 [Google Scholar]
29. Kara RJ, Bolli P, Karakikes I. 29.  et al. 2012. Fetal cells traffic to injured maternal myocardium and undergo cardiac differentiation. Circ. Res. 110:82–93 [Google Scholar]
30. Karaye KM, Yahaya IA, Lindmark K, Henein MY. 30.  2015. Serum selenium and ceruloplasmin in Nigerians with peripartum cardiomyopathy. Int. J. Mol. Sci. 16:7644–54 [Google Scholar]
31. Cenac A, Sacca-Vehounkpe J, Poupon J. 31.  et al. 2009. Sélénium plasmatique et cardiomyopathie dilatée à Cotonou (Bénin) [Serum selenium and dilated cardiomyopathy in Cotonou, Benin]. Med. Trop. (Mars) 69272–74 [Google Scholar]
32. Karaye KM, Lindmark K, Henein MY. 32.  2017. Prevalence and predictors of right ventricular diastolic dysfunction in peripartum cardiomyopathy. J. Echocardiogr. 15:135–40 [Google Scholar]
33. Bello NA, Arany Z. 33.  2015. Molecular mechanisms of peripartum cardiomyopathy: a vascular/hormonal hypothesis. Trends Cardiovasc. Med. 25:6499–504 [Google Scholar]
34. Ware JS, Li J, Mazaika E. 34.  et al. 2016. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N. Engl. J. Med. 374:233–41 [Google Scholar]
35. Triebel J, Bertsch T, Bollheimer C. 35.  et al. 2015. Principles of the prolactin/vasoinhibin axis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 309:R1193–203 [Google Scholar]
36. Hilfiker-Kleiner D, Kaminski K, Podewski E. 36.  et al. 2007. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128:589–600 [Google Scholar]
37. Bajou K, Herkenne S, Thijssen VL. 37.  et al. 2014. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nat. Med. 20:741–7 [Google Scholar]
38. Halkein J, Tabruyn SP, Ricke-Hoch M. 38.  et al. 2013. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J. Clin. Investig. 123:2143–54 [Google Scholar]
39. Odiete O, Hill MF, Sawyer DB. 39.  2012. Neuregulin in cardiovascular development and disease. Circ. Res. 111:1376–85 [Google Scholar]
40. Carmeliet P, Jain RK. 40.  2011. Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307 [Google Scholar]
41. Powe CE, Levine RJ, Karumanchi SA. 41.  2011. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123:2856–69 [Google Scholar]
42. Patten IS, Rana S, Shahul S. 42.  et al. 2012. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485:333–38 [Google Scholar]
43. Hagberg CE, Falkevall A, Wang X. 43.  et al. 2010. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464:917–21 [Google Scholar]
44. Shahul S, Medvedofsky D, Wenger JB. 44.  et al. 2016. Circulating antiangiogenic factors and myocardial dysfunction in hypertensive disorders of pregnancy. Hypertension 67:61273–80 [Google Scholar]
45. Bdolah Y, Lam C, Rajakumar A. 45.  et al. 2008. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?. Am. J. Obstet. Gynecol. 198:428.e1–6 [Google Scholar]
46. Nonhoff J, Ricke-Hoch M, Mueller M. 46.  et al. 2017. Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy. Cardiovasc. Res. 113:6598–608 [Google Scholar]
47. Damp J, Givertz MM, Semigran M. 47.  et al. 2016. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy: results of the multicenter IPAC Study. JACC Heart Fail 4:380–88 [Google Scholar]
48. Lim R, Acharya R, Delpachitra P. 48.  et al. 2015. Activin and NADPH-oxidase in preeclampsia: insights from in vitro and murine studies. Am. J. Obstet. Gynecol. 212:86.e1–12 [Google Scholar]
49. Venkatesha S, Toporsian M, Lam C. 49.  et al. 2006. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12:642–49 [Google Scholar]
50. Ware JS, Li J, Mazaika MA. 50.  et al. 2016. Shared genetic etiology of peripartum and dilated cardiomyopathies. N. Engl. J. Med. 374:233 [Google Scholar]
51. Linke WA, Hamdani N. 51.  2014. Gigantic business: titin properties and function through thick and thin. Circ. Res. 114:1052–68 [Google Scholar]
52. Spudich JA. 52.  2014. Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys. J. 106:1236–49 [Google Scholar]
53. Kruger M, Kotter S. 53.  2016. Titin, a central mediator for hypertrophic signaling, exercise-induced mechanosignaling and skeletal muscle remodeling. Front. Physiol. 7:76 [Google Scholar]
54. Herman DS, Lam L, Taylor MR. 54.  et al. 2012. Truncations of titin causing dilated cardiomyopathy. N. Engl. J. Med. 366:619–28 [Google Scholar]
55. Roberts AM, Ware JS, Herman DS. 55.  et al. 2015. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci. Transl. Med. 7:270ra6 [Google Scholar]
56. Mallikethi-Reddy S, Akintoye E, Trehan N. 56.  et al. 2017. Burden of arrhythmias in peripartum cardiomyopathy: analysis of 9841 hospitalizations. Int. J. Cardiol. 235:114–17 [Google Scholar]
57. Elkayam U. 57.  2011. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J. Am. Coll. Cardiol. 58:659–70 [Google Scholar]
58. Greer IA. 58.  2015. Pregnancy complicated by venous thrombosis. N. Engl. J. Med. 373:540–47 [Google Scholar]
59. Duncker D, Haghikia A, Konig T. 59.  et al. 2014. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur. J. Heart Fail. 16:1331–36 [Google Scholar]
60. Duncker D, Westenfeld R, Konrad T. 60.  et al. 2017. Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clin. Res. Cardiol. 106:582–89 [Google Scholar]
61. Sliwa K, Blauwet L, Tibazarwa K. 61.  et al. 2010. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 121:1465–73 [Google Scholar]
62. Haghikia A, Podewski E, Libhaber E. 62.  et al. 2013. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res. Cardiol. 108:366 [Google Scholar]
63. Isogai T, Matsui H, Tanaka H. 63.  et al. 2017. In-hospital management and outcomes in patients with peripartum cardiomyopathy: a descriptive study using a national inpatient database in Japan. Heart Vessels 32:944–51 [Google Scholar]
64. US Food, Drug Administration. 64.  1995. Sandoz Pharmaceutical Corp.; bromocriptine mesylate (Parlodel); withdrawal of approval of the indication for the prevention of physiological lactation. Fed. Regist 603404–5 [Google Scholar]
65. McNamara DM, Elkayam U, Alharethi R. 65.  et al. 2015. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J. Am. Coll. Cardiol. 66:905–14 [Google Scholar]
66. Black RE, Victora CG, Walker SP. 66.  et al. 2013. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet 382:427–51 [Google Scholar]
67. Haghikia A, Podewski E, Berliner D. 67.  et al. 2015. Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. Clin. Res. Cardiol. 104:911–17 [Google Scholar]
68. Thadhani R, Hagmann H, Schaarschmidt W. 68.  et al. 2016. Removal of soluble Fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J. Am. Soc. Nephrol. 27:3903–13 [Google Scholar]
69. Harper MA, Meyer RE, Berg CJ. 69.  2012. Peripartum cardiomyopathy: population-based birth prevalence and 7-year mortality. Obstet. Gynecol. 120:1013–19 [Google Scholar]
70. Goland S, Modi K, Hatamizadeh P, Elkayam U. 70.  2013. Differences in clinical profile of African-American women with peripartum cardiomyopathy in the United States. J. Cardiac Fail. 19:214–18 [Google Scholar]
71. Kamiya CA, Kitakaze M, Ishibashi-Ueda H. 71.  et al. 2011. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese nationwide survey of peripartum cardiomyopathy. Circ. J. 75:1975–81 [Google Scholar]
72. Ntusi NB, Badri M, Gumedze F. 72.  et al. 2015. Pregnancy-associated heart failure: a comparison of clinical presentation and outcome between hypertensive heart failure of pregnancy and idiopathic peripartum cardiomyopathy. PLOS ONE 10:e0133466 [Google Scholar]
73. Blauwet LA, Libhaber E, Forster O. 73.  et al. 2013. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. Heart 99:308–13 [Google Scholar]
74. Gambahaya ET, Hakim J, Kao D. 74.  et al. 2017. Peripartum cardiomyopathy among cardiovascular patients referred for echocardiography at Parirenyatwa Teaching Hospital, Harare, Zimbabwe. Cardiovasc. J. Afr. 28:8–13 [Google Scholar]
75. Rasmusson K, Brunisholz K, Budge D. 75.  et al. 2012. Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J. Heart Lung Transplant. 31:180–86 [Google Scholar]
76. Loyaga-Rendon RY, Pamboukian SV, Tallaj JA. 76.  et al. 2014. Outcomes of patients with peripartum cardiomyopathy who received mechanical circulatory support. Data from the Interagency Registry for Mechanically Assisted Circulatory Support. Circ. Heart Fail. 7:300–9 [Google Scholar]
77. Goland S, Bitar F, Modi K. 77.  et al. 2011. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J. Cardiac Fail. 17:426–30 [Google Scholar]
78. Luk K, Bakhsh A, Giannetti N. 78.  et al. 2017. Recovery in patients with dilated cardiomyopathy with loss-of-function mutations in the titin gene. JAMA Cardiol 2:6700–2 [Google Scholar]
79. Hilfiker-Kleiner D, Haghikia A, Masuko D. 79.  et al. 2017. Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur. J. Heart Fail. In press
80. Lampert MB, Weinert L, Hibbard J. 80.  et al. 1997. Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am. J. Obstet. Gynecol. 176:189–95 [Google Scholar]
81. Goland S, Modi K, Bitar F. 81.  et al. 2009. Clinical profile and predictors of complications in peripartum cardiomyopathy. J. Cardiac Fail. 15:645–50 [Google Scholar]
82. Amos AM, Jaber WA, Russell SD. 82.  2006. Improved outcomes in peripartum cardiomyopathy with contemporary. Am. Heart J. 152:509–13 [Google Scholar]